Mingarro-de-Le—n A, Chaveli-L—pez B. Alternative to oral dicoumarin anticoagulants: Considerations in dental care. J Clin Exp Dent. 2013;5(5):e273-8.

 

doi:10.4317/jced.51226

http://dx.doi.org/doi:10.4317/jced.51226

 

References

1. Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: Biology and dental implications. Med Oral Patol Oral Cir Bucal. 2013;18:e461-72.

http://dx.doi.org/10.4317/medoral.19140

PMid:23524440 PMCid:PMC3668874                                                      

                                                                     

2. Kosyfaki P, Att W, Strub JR. The dental patient on oral anticoagulant medication: a literature review. J Oral Rehabil. 2011;38:615-33.

http://dx.doi.org/10.1111/j.1365-2842.2010.02184.x

PMid:21073495                                                                   

                                                                     

3. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-60.

http://dx.doi.org/10.1016/j.amjcard.2012.03.049

PMid:22537354                                                                   

                                                                     

4. Claramunt Lozano A, Sarri—n Perez MG, Gavald‡ Esteve C. Dental management in patients with hemostasis alteration. J Clin Exp Dent. 2011;3:e120-6.

http://dx.doi.org/10.4317/jced.3.e120                                                     

                                  

5. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.

http://dx.doi.org/10.1093/eurheartj/ehq278

PMid:20802247                                                                   

                                                                     

6. JimŽnez Y, Poveda R, Gavald‡ C, Margaix M, Sarri—n G. An update on the management of anticoagulated patients programmed for dental extractions and surgery. Med Oral Patol Oral Cir Bucal. 2008;13:E176-9.

PMid:18305438                                                                   

                                                                     

7. Zapata Wainberg G, XimŽnez-Carrillo Rico A, Vivancos Mora J. Clinical management of the new anticoagulants. Neurologia. 2012;27:33-8.

http://dx.doi.org/10.1016/S0213-4853(12)70006-3                                                        

 PMid: 22682208

                 

8. Haremberg J, Wehling M. Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa. Semin Thromb Haemost. 2008;39:57.                                                                         

 

9. Marco P, Tar’n F, Lucas J. New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics. Med Clin (Barc). 2008; 131: 66-9.

http://dx.doi.org/10.1016/S0025-7753(08)76452-2                                                        

PMid: 19087854

 

10. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-41.

http://dx.doi.org/10.1016/j.oooo.2011.10.005

PMid:22668425                                                                   

                                                                     

11. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol. 2012;11:1066-81.

http://dx.doi.org/10.1016/S1474-4422(12)70258-2                                                        

 PMid: 23153406

 

12. P‡ramo JA. Hemorrhage, hemostasis and thrombosis in surgery. Cir Esp. 2009;85:2-6.

http://dx.doi.org/10.1016/S0009-739X(09)71621-5                                                        

 PMid: 19589403

                 

13. Garc’a-Ch‡vez J. The new oral anticoagulants in surgery. Rev Med Inst Mex Seguro Soc. 2011;49:393-9.

PMid:21982189                                                                   

                                                                     

14. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-91.

http://dx.doi.org/10.1161/CIRCULATIONAHA.112.115410

PMid:23071159                                                                   

                                                                     

15. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575-80.

http://dx.doi.org/10.1016/j.oooo.2011.10.006

PMid:22668618                                                                   

                                                                     

16. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.

http://dx.doi.org/10.1146/annurev-med-062209-095159

PMid:21226611                                                                   

                                                                     

17. Liem TK, Deloughery TG. Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. Semin Vasc Surg. 2011;24:157-61.

http://dx.doi.org/10.1053/j.semvascsurg.2011.11.003

PMid:22153026                                                                   

                                                                     

18. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108:476-84.

http://dx.doi.org/10.1160/TH12-02-0093

PMid:22740145                                                                   

                                                                     

19. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.

http://dx.doi.org/10.1056/NEJMoa0905561

PMid:19717844                                                                   

                                                                     

20. Turpie AG. Rivaroxaban for the prevention and treatment of venous thromboembolism. Fundam Clin Pharmacol. 2012; 26:33-8.

http://dx.doi.org/10.1111/j.1472-8206.2011.00980.x

PMid:21851388                                                                   

                                                                     

21. EINSTEIN–PE Investigators, BŸller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510.

http://dx.doi.org/10.1056/NEJMoa1007903

PMid:21128814                                                                   

                                                                     

22. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:711-9.

http://dx.doi.org/10.1161/CIRCOUTCOMES.112.966572

PMid:22912382                                                                   

                                                                     

23. Karthikeyan G, Eikelboom JW, Hirsh J. New oral anticoagulants: not quite there yet. Pol Arch Med Wewn. 2009;119:53-8.

PMid:19341179                                                                   

                                                                     

24. Tsiara S, Pappas K, Boutsis D, Laffan M. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol. 2011;52:52-67.

PMid:21292607                                                                   

                                                                     

25. Rasmussen LH, Larsen TB, Graungaard T, Skj¿th F, Lip GY. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097.

http://dx.doi.org/10.1136/bmj.e7097

PMid:23129490 PMCid:PMC3489505                                                      

                                                                     

26. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498.

http://dx.doi.org/10.1136/bmj.e7498

PMid:23150473 PMCid:PMC3496553                                                      

                                                                     

27. Brenner B, Hoffman R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Rev. 2011;25:215-21.

http://dx.doi.org/10.1016/j.blre.2011.04.003

PMid:21605928                                                                   

                                                                     

28. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S-198S.                                                                                                      

PMid: 18574265

                                                                                                                                                                                                                                                                                                                                                                                    

                                                                     

29. Aalbers J. Anti-thrombotic trials in atrial fibrillation, the RELY study. Cardiovasc J Afr. 2010;21:299.

PMid:20972524                                                                   

                                                                     

30. Soff GA. A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol. 2012;32:569-74.

http://dx.doi.org/10.1161/ATVBAHA.111.242834

PMid:22345595                                                                   

                                                                     

31. Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol. 2012;25:351-60.

http://dx.doi.org/10.1016/j.beha.2012.06.004

PMid:22959551                                                                   

                                                                     

32. Scully C, Wolff A. Oral surgery in patients on anticoagulant therapy. Oral Surg Oral Med Oral Pathol Oral Radiol endod. 2002; 94:57-64.

http://dx.doi.org/10.1067/moe.2002.123828                                                       

                                                                     

33. Baumann Kreuziger LM, Morton CT, Dries DJ. New anticoagulants: A concise review. J Trauma Acute Care Surg. 2012;73:983-92.

http://dx.doi.org/10.1097/TA.0b013e318265cf9e

PMid:22976421                                                                   

                                                                     

34. Vargas Ruiz AG, Ram’rez L—pez AN, Medina Viramontes ME. New anticoagulants: dabigatran, rivaroxaban and apixaban. Gac Med Mex. 2012;148:257-64.

PMid:22820359                                                                   

                                                                     

35. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954-62.

http://dx.doi.org/10.1182/blood-2012-06-415943

PMid:22932800                                                                   

                                                                     

36. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.

http://dx.doi.org/10.1160/TH09-11-0758

PMid:20352166                                                                   

                                                                     

37. Aframian DJ, Lalla RV, Peterson DE. Management of dental patients taking common hemostasis-altering. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:S45.e1-11.                                                                                                                                                                                                                                                                                                                                                                

PMid:                                                                                                                                                                                                                                                                                                                                                                       

                                                                     

38. Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-6.

http://dx.doi.org/10.1097/ACO.0b013e32832eb8ab

PMid:19568169